Menz G, Rothe T, Schmitt M, Schmitz M, Hauser F, Haack D, Virchow C
Hochgebirgsklinik Davos, Wolfgang.
Pneumologie. 1990 Feb;44 Suppl 1:238-40.
Although treatment comprising a combination of methylprednisolone (MP) and troleandomycin (TAO) has been employed to treat cases of severe bronchial asthma requiring high doses of corticosteroids, for about 20 years, now, it has always been associated with major adverse reactions (1). A new protocol avoids these adverse effects by a rapid reduction in the dose of MP to alternating administrations and low TAO dosage (250 mg). Nineteen patients were treated using this protocol, 16 of whom for more than two months (maximum 21, minimum 4 months). Three patients were taken out of the study as early non-responders in the initial phase. Five patients must be considered to be late non-responders, or were discharged from the study on account of pathological liver parameters. In 8 patients who showed good tolerance, an appreciable reduction in the dose of steroids, with stabilisation of the asthma, was observed.
尽管包含甲泼尼龙（MP）和醋竹桃霉素（TAO）的联合治疗已被用于治疗需要高剂量皮质类固醇的重度支气管哮喘病例约20年，但它一直与严重不良反应相关（1）。一种新方案通过迅速降低MP剂量至交替给药以及低剂量TAO（250毫克）来避免这些不良反应（2）。19名患者采用该方案进行治疗，其中16名治疗时间超过两个月（最长21个月，最短4个月）。3名患者在初始阶段作为早期无反应者退出研究。5名患者必须被视为晚期无反应者，或者因肝脏病理参数而退出研究。在8名耐受性良好的患者中，观察到类固醇剂量明显减少，哮喘病情稳定。
